Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

Novo Nordisk (NVO) reports Q4 earnings with expectations of 86 cents EPS and $11.40B revenues. Stock down 29.55% YOY, 4.81% ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk. If we consider the specifics of ...

On the charts, today's pop has NVO on track to snap a three-day losing streak. The stock still hasn't recovered from its ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Pen Needles Market Insight BURLINGAME, CA, UNITED STATES, February 5, 2025 /EINPresswire / -- The Pen Needles Market Report is the result of e ...

After hours: 7:59:50 p.m. EST Loading Chart for NVO ...